Greenwich Lifesciences Net Worth
Greenwich Lifesciences Net Worth Breakdown | GLSI |
Greenwich Lifesciences Net Worth Analysis
Greenwich Lifesciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Greenwich Lifesciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Greenwich Lifesciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Greenwich Lifesciences' net worth analysis. One common approach is to calculate Greenwich Lifesciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Greenwich Lifesciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Greenwich Lifesciences' net worth. This approach calculates the present value of Greenwich Lifesciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Greenwich Lifesciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Greenwich Lifesciences' net worth. This involves comparing Greenwich Lifesciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Greenwich Lifesciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Greenwich Lifesciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Greenwich Lifesciences' net worth research are outlined below:
| Greenwich Lifesciences had very high historical volatility over the last 90 days | |
| Greenwich Lifesciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (8.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Greenwich Lifesciences currently holds about 15.64 M in cash with (6.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. | |
| Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 53.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Greenwich LifeSciences, Inc. VP Purchases 12,910.00 in Stock |
Greenwich Lifesciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Greenwich Lifesciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Greenwich Lifesciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 27th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Greenwich Lifesciences Target Price Consensus
Greenwich target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Greenwich Lifesciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Buy |
Most Greenwich analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Greenwich stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Greenwich Lifesciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationGreenwich Lifesciences Target Price Projection
Greenwich Lifesciences' current and average target prices are 14.25 and 36.00, respectively. The current price of Greenwich Lifesciences is the price at which Greenwich Lifesciences is currently trading. On the other hand, Greenwich Lifesciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Greenwich Lifesciences Market Quote on 2nd of December 2024
Target Price
Analyst Consensus On Greenwich Lifesciences Target Price
Know Greenwich Lifesciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Greenwich Lifesciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Greenwich Lifesciences backward and forwards among themselves. Greenwich Lifesciences' institutional investor refers to the entity that pools money to purchase Greenwich Lifesciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of New York Mellon Corp | 2024-09-30 | 11.2 K | Millennium Management Llc | 2024-09-30 | 10.6 K | Barclays Plc | 2024-09-30 | 8.6 K | Bank Of America Corp | 2024-06-30 | 6.3 K | Rhumbline Advisers | 2024-09-30 | 6.3 K | New York State Common Retirement Fund | 2024-09-30 | 6 K | Citigroup Inc | 2024-09-30 | 4.3 K | Mirae Asset Global Etfs Holdings Ltd. | 2024-09-30 | 3.3 K | Corebridge Financial Inc | 2024-09-30 | 3.2 K | Blackrock Inc | 2024-06-30 | 308.9 K | Vanguard Group Inc | 2024-09-30 | 273.5 K |
Follow Greenwich Lifesciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 191.52 M.Market Cap |
|
Project Greenwich Lifesciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.27) | (1.34) | |
| Return On Capital Employed | (1.39) | (1.32) | |
| Return On Assets | (1.27) | (1.33) | |
| Return On Equity | (1.33) | (1.26) |
When accessing Greenwich Lifesciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Greenwich Lifesciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Greenwich Lifesciences' profitability and make more informed investment decisions.
Evaluate Greenwich Lifesciences' management efficiency
Greenwich Lifesciences has return on total asset (ROA) of (0.7245) % which means that it has lost $0.7245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2367) %, meaning that it created substantial loss on money invested by shareholders. Greenwich Lifesciences' management efficiency ratios could be used to measure how well Greenwich Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.34. The Greenwich Lifesciences' current Return On Capital Employed is estimated to increase to -1.32. As of now, Greenwich Lifesciences' Net Tangible Assets are increasing as compared to previous years. Other Assets is expected to grow at the current pace this year, while Total Assets are projected to decrease to under 6.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.52 | 0.47 | |
| Tangible Book Value Per Share | 0.52 | 0.47 | |
| Enterprise Value Over EBITDA | (13.75) | (14.43) | |
| Price Book Value Ratio | 20.17 | 21.18 | |
| Enterprise Value Multiple | (13.75) | (14.43) | |
| Price Fair Value | 20.17 | 21.18 | |
| Enterprise Value | 128.2 M | 240.3 M |
Leadership at Greenwich Lifesciences emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Return On Equity (1.24) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Greenwich Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Greenwich Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Greenwich Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Greenwich Lifesciences Corporate Filings
F4 | 25th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 1st of November 2024 Other Reports | ViewVerify | |
| 7th of October 2024 Other Reports | ViewVerify |
Greenwich Lifesciences Earnings Estimation Breakdown
The calculation of Greenwich Lifesciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Greenwich Lifesciences is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Greenwich Lifesciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Greenwich Lifesciences Earnings Projection Consensus
Suppose the current estimates of Greenwich Lifesciences' value are higher than the current market price of the Greenwich Lifesciences stock. In this case, investors may conclude that Greenwich Lifesciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Greenwich Lifesciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 1 | 73.87% | -0.2 | 0.0 | -0.81 |
Greenwich Lifesciences Earnings per Share Projection vs Actual
Actual Earning per Share of Greenwich Lifesciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Greenwich Lifesciences predict the company's earnings will be in the future. The higher the earnings per share of Greenwich Lifesciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Greenwich Lifesciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Greenwich Lifesciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Greenwich Lifesciences should always be considered in relation to other companies to make a more educated investment decision.Greenwich Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Greenwich Lifesciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-08 | 2024-09-30 | -0.21 | -0.2 | 0.01 | 4 | ||
2024-08-21 | 2024-06-30 | -0.2 | -0.2 | 0.0 | 0 | ||
2024-05-20 | 2024-03-31 | -0.2 | -0.19 | 0.01 | 5 | ||
2024-03-31 | 2023-12-31 | -0.22 | -0.2138 | 0.0062 | 2 | ||
2023-10-19 | 2023-09-30 | -0.22 | -0.1862 | 0.0338 | 15 | ||
2023-08-21 | 2023-06-30 | -0.23 | -0.13 | 0.1 | 43 | ||
2023-05-22 | 2023-03-31 | -0.23 | -0.16 | 0.07 | 30 | ||
2023-03-01 | 2022-12-31 | -0.18 | -0.22 | -0.04 | 22 | ||
2022-11-14 | 2022-09-30 | -0.19 | -0.18 | 0.01 | 5 | ||
2022-08-15 | 2022-06-30 | -0.19 | -0.06 | 0.13 | 68 | ||
2022-05-20 | 2022-03-31 | -0.19 | -0.15 | 0.04 | 21 | ||
2022-03-21 | 2021-12-31 | -0.07 | -0.18 | -0.11 | 157 | ||
2021-11-15 | 2021-09-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2021-08-13 | 2021-06-30 | -0.06 | -0.06 | 0.0 | 0 | ||
2021-05-20 | 2021-03-31 | -0.26 | -0.05 | 0.21 | 80 | ||
2021-03-31 | 2020-12-31 | -0.93 | -0.12 | 0.81 | 87 | ||
2020-09-28 | 2020-06-30 | 0 | -0.02 | -0.02 | 0 | ||
2020-06-23 | 2020-03-31 | 0 | -0.03 | -0.03 | 0 | ||
2020-01-28 | 2019-12-31 | 0 | -0.27 | -0.27 | 0 | ||
2019-09-30 | 2019-06-30 | 0 | -1.1516 | -1.1516 | 0 | ||
2019-06-30 | 2019-03-31 | 0 | -12.828 | -12.828 | 0 | ||
2019-03-31 | 2018-12-31 | 0 | -0.7327 | -0.7327 | 0 |
Greenwich Lifesciences Corporate Management
| Christine Fischette | VP Development | Profile | |
| Snehal Patel | CFO CEO | Profile | |
| Eric Rothe | Founder Director | Profile | |
| Frank MD | Chief Director | Profile | |
| Jaye Thompson | Vice Affairs | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Return On Assets (0.72) | Return On Equity (1.24) |
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.